Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483946 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL5498760 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL358119 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL361149 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL22163010 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL24722227 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL8497748 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL14831515 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL362251 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL14831148 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1080 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| EP-4611730-A1 | ORAL BIOLOGIC MACROMOLECULE DELIVERY SYSTEM | Nutrition & Biosciences USA 1, LLC (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250262317-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | HOFFMANN-LA ROCHE INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250222064-A1 | METHOD OF TREATMENT OF NEUTROPHIL-DRIVEN INFLAMMATORY PATHOLOGIES | WILD BOAR BIOSCIENCES, LLC | 2025-07-10 | — | — | US | claimed |
| WO-2025126115-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-19 | — | — | WO | claimed |
| EP-4558174-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-4514796-A1 | CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-03-05 | — | — | EP | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2024227868-A1 | SELF-ASSEMBLING PEPTIDE AMPHIPHILES AS RETROVIRAL TRANSDUCTION ENHANCERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-11-07 | — | — | WO | claimed |
| WO-2002007676-A2 | COMPOUNDS HAVING AFFINITY FOR THE GRANULOCYTE-COLONY STIMULATING FACTOR RECEPTOR (G-CSFR) | GLAXO GROUP LIMITED (GB) | 2002-01-31 | — | — | WO | claimed |
| CN-1202882-A | Novel LH-RH antagonists with improved action | ASTA MEDICA AG (DE) | 1998-12-23 | — | — | CN | claimed |
| EP-0555229-B1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES | LIPOSOME CO INC (US) | 1996-06-05 | — | — | EP | claimed |
| US-5290794-A | Storage stable compositions | WARNER LAMBERT CO. (US) | 1994-03-01 | — | — | US | claimed |
| EP-0555229-A1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES. | LIPOSOME CO INC (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0555229-A4 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES. | LIPOSOME CO INC (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1992002244-A1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 1992-02-20 | — | — | WO | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| US-4138292-A | ENZYMES OR MICROORGANISMS IN A SULFATED POLYSACCHARIDE GEL | TANABE SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262317-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | DAO, RNGTT, CTDSP1 | GSR 4376/4885RNPEP 241/4885GNAI3 4246/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | GSR 2517/4885RNPEP 2363/4885GNAI3 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.